Phil Greenberg

Phil Greenberg leads the Program in Immunology at the Fred Hutchinson Cancer Research Center in Seattle. He has been instrumental in the discovery of the principles of T-cell and tumor interactions and translating key insights to cancer therapies with genetically engineered T cells. Phil is also the scientific co-founder of Juno Therapeutics, which was acquired for $9B by Celgene in 2018. He served as an elected member of the Board of Directors of the American Association for Cancer Research, and currently is an Editor-In-Chief of the journal Cancer Immunology Research. As frequently as possible, Phil escapes to the slopes in Whistler or Crystal Mountain for skiing.